| Name | Title | Contact Details |
|---|
Vanda Pharmaceuticals (NASDAQ: VNDA) is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders to address unmet needs. The company has assembled an experienced team along with a portfolio of clinical and commercial stage programs with the goal of bringing important new treatment options to patients.
NMT Medical, Inc. is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CoreLink Administrative Solutions was launched on January 1, 2009, as a new concept in health care benefits technology. We provide the technology that allows multiple companies to share common core systems and services, resulting in significant cost savings, gains in efficiency and improved capabilities to provide enhanced services. CoreLink is a long-term IT investment funded by Blue Cross Blue Shield of Nebraska and Blue Cross Blue Shield of North Dakota. Working together, the technology experts have built an infrastructure capitalizing on the strengths and experience of both Plans. This investment provides the means to efficiently address the ongoing changes in the health care environment and challenges posed by regulatory requirements, which can add significant costs to Plan operations.
We are dedicated to delivering excellent customer service as we build and maintain an environment that balances the needs of our valued employees and the organization. Our development of policies, programs, and services will promote accountability, involvement, diversity, and high performance, while ensuring compliance.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.